StockpollyBeta
Get App
Popularity #4,822
LONA · NASDAQ · Biotechnology

LeonaBio (LONA)

Develops lasofoxifene for metastatic breast cancer and ATH-1105 for ALS.

$6.05
After hours+0.07 (+1.17%)
At close$5.98(−5.53%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue0000000006800
Gross profit000000000−6800
352927283016977101819
Research & development2724212218944371113
876686544477
General & administrative876686544477
Other expenses0−20040000000
Operating income−35−29−28−28−30−16−10−7−7−79−18−19
221111000−4−150
Interest income221111000010
Interest expense020000000000
Other non-operating income0200−40000−6800
Income before tax−33−27−26−27−29−15−9−7−7−83−33−19
Net income from continuing operations−33−27−26−27−29−15−9−7−7−83−33−19
Net income−33−27−26−27−29−15−9−7−7−83−33−19
EPS, basic−$8.70−$7.20−$6.90−$7.00−$7.50−$3.90−$2.30−$1.78−$1.68−$18.94−$7.71−$4.45
EPS, diluted−$8.70−$7.20−$6.90−$7.00−$7.50−$3.90−$2.30−$1.78−$1.68−$18.94−$7.71−$4.45
Weighted average shares, basic444444444444
Weighted average shares, diluted444444444444
EBITDA−35−30−27−28−25−15−9−7−7−10−18−19
Depreciation & amortization000000000000
EBIT−35−31−28−28−25−16−9−7−7−10−18−19